Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

PURPOSE: This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Nogova, Lucia, Sequist, Lecia V., Perez Garcia, Jose Manuel, Andre, Fabrice, Delord, Jean-Pierre, Hidalgo, Manuel, Schellens, Jan H.M., Cassier, Philippe A., Camidge, D. Ross, Schuler, Martin, Vaishampayan, Ulka, Burris, Howard A., Tian, G. Gary, Campone, Mario, Wainberg, Zev A., Lim, Wan-Teck, LoRusso, Patricia, Shapiro, Geoffrey I., Parker, Katie, Chen, Xueying, Choudhury, Somesh, Ringeisen, Francois, Graus-Porta, Diana, Porter, Dale, Isaacs, Randi, Buettner, Reinhard, Wolf, Jürgen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2017
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865065/
https://ncbi.nlm.nih.gov/pubmed/27870574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.2048
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller